Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Eli Lilly said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk will soon announce the results of perhaps the most ambitious studies yet of its GLP-1 drug: whether it can help ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment ...

A rebound in Denmark’s pharmaceutical industry, dominated by Novo Nordisk A/S, powered the economy to its fastest quarterly ...

Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of ...

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...